Get the Stockscreener App
4.00
0.50%
0.02
After Hours:
4.00
X 4 Pharmaceuticals Inc stock is traded at $4.00, with a volume of 463.48K.
It is up +0.50% in the last 24 hours and up +2.83% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$3.98
Open:
$3.98
24h Volume:
463.48K
Relative Volume:
0.75
Market Cap:
$349.75M
Revenue:
$32.77M
Net Income/Loss:
$-101.98M
P/E Ratio:
-0.4162
EPS:
-9.6101
Net Cash Flow:
$-112.43M
1W Performance:
+8.11%
1M Performance:
+2.83%
6M Performance:
+150.00%
1Y Performance:
-77.78%
1-Day Range:
$3.795
$4.00
1-Week Range:
$3.59
$4.00
52-Week Range:
$1.35
$19.69
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.00 | 348.00M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.61 | 119.76B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.18 | 79.35B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
851.72 | 51.71B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
351.80 | 44.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.38 | 38.18B | 4.98B | 69.60M | 525.67M | 0.5198 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026 - Yahoo Finance
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives $34.50 Average PT from Brokerages - Defense World
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X4 Pharmaceuticals announces inducement grants under Nasdaq Listing Rule - marketscreener.com
New X4 Pharmaceuticals hires get options at $3.70 a share - Stock Titan
Moving Averages: How much upside does X4 Pharmaceuticals Inc have2025 Buyback Activity & Low Risk High Win Rate Picks - baoquankhu1.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
More Than 30,000 Prescribed Cholesterol Drugs Recalled Nationwide - The Healthy @Reader's Digest
Layoff Tracker: Gilead Continues California Cuts With 34 Laid Off - BioSpace
Subdued Growth No Barrier To Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) With Shares Advancing 25% - simplywall.st
Exit Recap: Is X4 Pharmaceuticals Inc stock a value trapWeekly Stock Recap & AI Driven Stock Movement Reports - baoquankhu1.vn
Budget pitch: Pharma Inc seeks tax breaks for research and development - The Economic Times
Pfizer Inc. | Pharmaceuticals, Vaccines & Company History | Britannica Money - Britannica
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Soleno Therapeutics, Inc. (NASDAQ:SLNO) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Tarsus Pharmaceuticals, Inc. $TARS Shares Purchased by Jennison Associates LLC - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat
Telehealth deal lets U.S. travelers secure weekly malaria prevention pre-trip - Stock Titan
31,152 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Rakuten Investment Management Inc. - MarketBeat
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Aug Breakouts: What is the long term forecast for X4 Pharmaceuticals Inc stockJuly 2025 Opening Moves & High Accuracy Buy Signal Tips - baoquankhu1.vn
Lilly, Takeda targeted by legal strategy usually reserved for the mob - Pharma Voice
Corvus eczema drug improves key symptoms for 75% in early trial - Stock Titan
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Presents a Compelling Value Investment Case - Chartmill
Sun Pharma places non-binding offer for US-based Organon in its boldest global bet ever - The Economic Times
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by ASR Vermogensbeheer N.V. - MarketBeat
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are individual investors with 52% ownership, institutions own 31% - Yahoo Finance
Quarterly Trades: Is AXSPRE attractive at current valuationWeekly Gains Summary & Fast Moving Stock Watchlists - baoquankhu1.vn
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by PGGM Investments - MarketBeat
Rhythm Pharmaceuticals, Inc. $RYTM Holdings Lifted by Nisa Investment Advisors LLC - MarketBeat
Nasdaq-listed 60 Degrees Pharma shrinks shares 4-for-1 on Jan. 20 reverse - Stock Titan
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Could Be Riskier Than It Looks - simplywall.st
Market Recap: What Wall Street predicts for X4 Pharmaceuticals Inc stock priceBear Alert & Accurate Buy Signal Alerts - Bộ Nội Vụ
Gains Report: How X4 Pharmaceuticals Inc stock reacts to inflationary pressuresM&A Rumor & Consistent Profit Trading Strategies - Bộ Nội Vụ
Aug Fed Impact: Can X4 Pharmaceuticals Inc stock deliver 10 annual returnsWeekly Stock Recap & AI Based Buy/Sell Signal Reports - Bộ Nội Vụ
p-Chip Corporation, Choice One Rx, and RxERP Launch Precedent-Setting Trial Demonstrating Digital Traceability of Drug Supply Chains and Chain-of-Identity for DSCSA Compliance, Co-Sponsored by Avantor - Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
All You Need to Know About X4 Pharmaceuticals (XFOR) Rating Upgrade to Buy - Yahoo Finance
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals - BioSpace
Amylyx Pharmaceuticals (AMLX) Valuation Check As New GLP-1 Candidate AMX0318 Enters Development Stage - Yahoo Finance
Why X4 Pharmaceuticals Inc. stock remains resilientQuarterly Risk Review & Daily Oversold Stock Bounce Ideas - ulpravda.ru
RYTM Stock Jumps 4% On Imcivree Revenue Growth: Firm Awaits Approval In Acquired Hypothalamic Obesity By March - Stocktwits
Mirum Pharmaceuticals begins Phase 2 trial for Fragile X syndrome drug By Investing.com - Investing.com South Africa
Why X4 Pharmaceuticals Inc. (48Q0) stock fits value portfoliosJuly 2025 Breakouts & Free Real-Time Market Sentiment Alerts - Улправда
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27% - simplywall.st
Can X4 Pharmaceuticals Inc. stock deliver sustainable ROEInsider Selling Patterns & Investment Risk Management Tips - Улправда
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Given Consensus Rating of “Hold” by Analysts - Defense World
Europe reviews first nose-spray patients could use for sudden PSVT - Stock Titan
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
X 4 Pharmaceuticals Inc Stock (XFOR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
May 16 '25 |
Buy |
2.48 |
1,032 |
2,561 |
25,337 |
1.22%
2.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):